Category: Federal Forum Posters
Purpose: With the emergence of new Hepatitis C Virus (HCV) therapies, treatment has rapidly evolved over the last five years. Standard treatment now includes direct-acting antiviral agents, with cure rates of over 90% for those completing the recommended regimen. Adherence is a crucial component of treating HCV. Non-adherence may increase the risk of treatment failure and the development of resistance associated variants. The purpose of this medication use evaluation (MUE) is to identify patients within the Bay Pines VA Healthcare System (VAHCS) who did not complete the recommended course of HCV therapy, determine reasons for discontinuation, and evaluate their clinical response.
Methods: A retrospective chart review will be conducted to identify and evaluate patients treated for HCV between January 1st 2015 and July 1st 2018 within the Bay Pines VAHCS who were treated with sofosbuvir/velpatasvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), elbasvir/grazoprevir (Zepatier), glecaprevir/pibrentasvir (Mavyret), or sofosbuvir/velpatasvir/voxilaprevir (Vosevi) and discontinued therapy prior to completion of the full recommended HCV treatment course. Patients that are identified to have prematurely discontinued HCV therapy will be further evaluated for reasons for discontinuation and virologic response as defined as HCV viral load twelve weeks after discontinuation. All data that is collected will be de-identified and stored in an excel spreadsheet located in a secure shared pharmacy network folder.
Results: Not applicable
Conclusion: Not applicable
Nicole Doyle– PGY1 Pharmacy Resident, Bay Pines Veterans Affairs Healthcare System, Fort Myers, FL